Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -71.23% is 17% below its 5-year average of -61.11%, around the middle of its 5-year range (-130.48%–-32.04%).
16.62% below its 12-month average of -61.08%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -19.14%.
RETURN ON ASSETS (ROA)
-71.23%
RETURN ON ASSETS (ROA) AVG TTM
-61.08%
RETURN ON ASSETS (ROA) AVG 3Y
-51.04%
RETURN ON ASSETS (ROA) AVG 5Y
-61.11%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.62%
CURRENT VS 3Y AVG
-39.57%
CURRENT VS 5Y AVG
-16.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
-144.36%
vs the sector median at left
Bolt Biotherapeutics, Inc.
Market Cap
$6.76M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
Market Cap
$6.83M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
Market Cap
$6.67M
Return on Assets (ROA)
-97.60%
TTM Avg
-274.34%
3Y Avg
-160.93%
5Y Avg
-165.76%
Market Cap
$6.94M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$6.47M
Return on Assets (ROA)
-426.88%
TTM Avg
-139.62%
3Y Avg
-270.47%
5Y Avg
-207.15%
Market Cap
$7.09M
Return on Assets (ROA)
-1082.20%
TTM Avg
-652.69%
3Y Avg
-445.69%
5Y Avg
-363.52%
Market Cap
$7.20M
Return on Assets (ROA)
-106.57%
TTM Avg
-92.47%
3Y Avg
-315.20%
5Y Avg
-267.86%
Market Cap
$6.27M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$7.33M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.76M | -71.23% | -61.08% | -51.04% | -61.11% |
| Aclarion, Inc. (ACON)vs › | $6.83M | -50.98% | -191.11% | -206.10% | -240.87% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | -97.60% | -274.34% | -160.93% | -165.76% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | -283.63% | -124.17% | -74.25% | -35.74% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.47M | -426.88% | -139.62% | -270.47% | -207.15% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.09M | -1082.20% | -652.69% | -445.69% | -363.52% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | -106.57% | -92.47% | -315.20% | -267.86% |
| Biomerica, Inc. (BMRA)vs › | $6.27M | -55.85% | -69.75% | -63.38% | -59.39% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.33M | -414.54% | -226.50% | -135.75% | -126.75% |
| Longeveron Inc. (LGVN)vs › | $7.33M | -151.57% | -141.88% | -132.44% | -101.65% |
ROA
-71.2%
ROE
-227.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -58.81% |
| 2024-12-31 | -63.35% |
| 2023-12-31 | -43.31% |
| 2022-12-31 | -38.67% |
| 2021-12-31 | -32.04% |
| 2020-12-31 | -130.48% |
| 2019-12-31 | -62.93% |
| 2018-12-31 | -72.54% |
